SABS SAB Biotherapeutics Inc

$SABS 🚀 Several bullish catalysts on the horizon! This one deserves more attention, IMO. 🔥 October 10: Two SAB-142 presentations at the Breakthrough T1D Congress, highlighting encouraging Phase 1 data, potential redosing benefits and early signals of insulin-producing beta-cell preservation. 🔥 Q4 2026: Targeted completion of enrollment in the Phase 2b SAFEGUARD trial — a meaningful clinical milestone! 🔥 2027: Anticipated SAFEGUARD topline results, a potentially major value-driving catalyst. 💰 Strong balance sheet: $208M in cash and investments as of June 30, with projected runway through 2028. SAB-142 has the potential to go beyond managing Type 1 diabetes symptoms and actually modify disease progression. With multiple milestones approaching, I’m looking for renewed investor interest and a nice rebound from these levels! 💪📈 Patience could pay off here! 👀

$SABS SAB BIO is presenting SAB-142 data today, September 30, at the EASD meeting in Milan. The presentations cover mechanism of action, C-peptide response, safe redosing/non-immunogenicity, and early efficacy signals in Type 1 diabetes.

$SABS I like the risk/reward after the recent pullback. SAB-142 continues progressing, fresh data is being presented at EASD, and the company has runway through 2028. Interesting setup at these levels — let’s see if buyers step in. 👀🚀

$SABS interesting to note that SAB Biotherapeutics developed human polyclonal antibodies targeting Yersinia pestis, the bacterium responsible for causing both pneumonic and bubonic plague ......

$SABS Five new positions have been added to the careers page on the SABS site in the last few weeks: Analytical Development Supervisor Director Analytical Development Senior Accountant Senior Research Associate 2, Analytical Development Vice President Program Management Also. note the European Association for the Study of Diabetes presentations start at 8:00am CST on Monday (9/28) and 6:00am CST on Wednesday (9/30).

$SABS reached measured move price projections of three degrees with bullish divergences on the technical indicators.